Stage II Vaginal Cancer
Squamous Cell Carcinoma
Adenocarcinoma
Current Clinical Trials
Squamous Cell Carcinoma
Radiation therapy is the standard treatment for patients with stage II vaginal carcinoma.
Standard treatment options:
- Combination of brachytherapy and external-beam radiation therapy (EBRT) to deliver
a combined dose of 70 Gy to 80 Gy to the primary tumor volume.[1] For
lesions of the lower third of the vagina, elective radiation therapy of 45 Gy to 50
Gy is given to the pelvic and/or inguinal lymph nodes.[1,2]
- Radical surgery (radical vaginectomy or pelvic exenteration) with or
without radiation therapy.[3,4]
Adenocarcinoma
Standard treatment options:
- Combination of brachytherapy and EBRT to deliver
a combined dose of 70 Gy to 80 Gy to the primary tumor.[1] For lesions of
the lower third of the vagina, elective radiation therapy of 45 Gy to 50 Gy is
given to the pelvic and/or inguinal lymph nodes.[1,2]
- Radical surgery (radical vaginectomy or pelvic exenteration) with or without
radiation therapy.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage II vaginal cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Perez CA, Camel HM, Galakatos AE, et al.: Definitive irradiation in carcinoma of the vagina: long-term evaluation of results. Int J Radiat Oncol Biol Phys 15 (6): 1283-90, 1988.
[PUBMED Abstract]
-
Andersen ES: Primary carcinoma of the vagina: a study of 29 cases. Gynecol Oncol 33 (3): 317-20, 1989.
[PUBMED Abstract]
-
Rubin SC, Young J, Mikuta JJ: Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. Gynecol Oncol 20 (3): 346-53, 1985.
[PUBMED Abstract]
-
Stock RG, Chen AS, Seski J: A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 56 (1): 45-52, 1995.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |